Prospective biomarkers in preterm preeclampsia: a review

Show simple item record

dc.contributor.author McCarthy, Fergus P.
dc.contributor.author Ryan, Roisin M.
dc.contributor.author Chappell, Lucy C.
dc.date.accessioned 2018-04-03T11:41:14Z
dc.date.available 2018-04-03T11:41:14Z
dc.date.issued 2018-03-23
dc.identifier.citation McCarthy, F. P., Ryan, R. M. and Chappell, L. C. (2018) 'Prospective biomarkers in preterm preeclampsia: a review', Pregnancy Hypertension, In Press, doi:10.1016/j.preghy.2018.03.010 en
dc.identifier.startpage 1 en
dc.identifier.endpage 32 en
dc.identifier.issn 2210-7789
dc.identifier.uri http://hdl.handle.net/10468/5722
dc.identifier.doi 10.1016/j.preghy.2018.03.010
dc.description.abstract Preterm pre-eclampsia (prior to 37 weeks’ gestation) remains a major cause of maternal and fetal morbidity and mortality particularly in low to middle income countries. Much research has focused on first and second trimester predictors of pre-eclampsia with the aim of allowing stratification of antenatal care and trialling of potential preventative and therapeutic agents. However, none have been shown to be of benefit in randomised controlled trials. In this literature review we critically evaluate predictive and diagnostic tests for preterm pre-eclampsia and discuss their clinical use and potential value in the management of preterm pre-eclampsia. We defined preterm pre-eclampsia as pre-eclampsia occurring prior to 37 weeks’ gestation. Substantial progress has been made in the development of predictive screening tests for preterm pre-eclampsia, but further research is needed prior to their introduction and integration into routine clinical practice. The performance of diagnostic tests mainly utilising angiogenic and anti-angiogenic factors for determining time to delivery in later pregnancy currently hold more promise than first trimester predictive tests, possible reflecting the heterogeneity of pre-eclampsia. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier en
dc.rights © 2018 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. en
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ en
dc.subject Hypertension en
dc.subject Preterm pre-eclampsia en
dc.subject Placental growth factor en
dc.subject Pregnancy en
dc.subject Screening en
dc.title Prospective biomarkers in preterm preeclampsia: a review en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Fergus P. McCarthy, Irish Centre for Fetal and Neonatal Translational Research, INFANT, University College Cork, Cork, Ireland. +353-21-490-3000 Email: fergus.mccarthy@ucc.ie en
dc.internal.availability Full text available en
dc.check.info Access to this article is restricted until 12 months after publication by request of the publisher. en
dc.check.date 2019-03-23
dc.description.version Accepted Version en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Pregnancy Hypertension en
dc.internal.copyrightchecked !!CORA!! en
dc.internal.IRISemailaddress fergus.mccarthy@ucc.ie en
dc.internal.bibliocheck In Press April 2018. Update citation details, page nos. Add vol. issue. Check for funding information en


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2018 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license. Except where otherwise noted, this item's license is described as © 2018 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement